Tuberculosis: First results from PARADIGM4TB, UNITE4TB’s flagship trial
19 Nov 2026
Two of ten new tuberculosis treatment combinations advance to further testing in UNITE4TB’s international phase 2 trial.
19 Nov 2026
Two of ten new tuberculosis treatment combinations advance to further testing in UNITE4TB’s international phase 2 trial.
The first results from PARADIGM4TB, UNITE4TB's international tuberculosis (TB) clinical trial, have been published in The New England Journal of Medicine (NEJM). The trial has identified two promising new 16-week treatment regimens that will now undergo further clinical evaluation.
One of the two selected regimens contains BTZ-043, developed by LMU University Hospital Munich and Leibniz-HKI, the other ganfeborole, developed by GSK. Both are investigational drugs with strong potential in TB treatment.
Tuberculosis remains one of the world's deadliest infectious diseases, causing more than one million deaths each year. The development of new therapeutic regimens remains slow, costly and complex, while treatment remains lengthy and treated patients face the burden of side effects. Accelerating the identification of safer, shorter and more effective treatment options is essential to achieving global TB elimination goals.
The publication in the NEJM marks a major milestone for the consortium and reflects the extraordinary effort required to establish an international trial network on this scale—not only to evaluate novel drug combinations, but also to pioneer innovative clinical trial methodologies. This achievement reflects the successful collaboration between academic researchers, the pharmaceutical industry, and TB community representatives.
PARADIGM4TB is UNITE4TB’s flagship Phase II, multi-arm, multi-stage (MAMS) platform trial. The first stage of the trial assessed 4 ganfeborole-containing regimens, 5 BTZ-043-containing regimens, one regimen that included both ganfeborole and BTZ-043 and a comparator regimen at a duration of 16 weeks against the 24-week standard-of-care control. The aim was to identify the regimens with the most favourable safety and efficacy profiles for evaluation in the second stage, which will assess their optimal treatment durations. The NEJM publication reports the 48-week outcomes of this first stage. University College London (UCL) sponsored the trial, whilst Radboud University Medical Center coordinates the UNITE4TB consortium overall.
"By testing multiple regimens simultaneously within a single trial platform, we were able to evaluate more treatment options in less time than traditional approaches allow. This is the kind of innovation needed if we are to accelerate the development of better TB treatments for patients worldwide,” says Hanif Esmail, Professor of Infectious Diseases at UCL and clinical lead for the PARADIGM4TB trial.
PARADIGM4TB enrolled 401 adults with rifampicin-susceptible pulmonary TB at 14 sites in five countries. The regimens' efficacy was assessed by comparing sputum clearance rates for tuberculosis with those in the standard-treatment arm over the first 12 weeks, and by comparing the proportions of participants with a favourable clinical outcome (no treatment failure or relapse) at week 48.
The trial identified the regimen combining bedaquiline, pretomanid, moxifloxacin and ganfeborole as the most promising ganfeborole-containing regimen. The most promising BTZ-043-containing regimen combined bedaquiline, delamanid, moxifloxacin and BTZ-043. The regimen combining bedaquiline, pyrazinamide, moxifloxacin and BTZ-043 was associated with a safety signal for excess liver toxicity.
The novel drugs ganfeborole and BTZ-043 inhibit distinct bacterial processes: ganfeborole (GSK3036656) inhibits leucyl-tRNA synthetase, stopping bacterial protein synthesis, while BTZ-043 inhibits DprE1, an essential enzyme for cell wall assembly. Both candidates previously demonstrated strong early bactericidal activity against Mycobacterium tuberculosis in early clinical studies. “As developers of BTZ-043, we are greatly encouraged by the PARADIGM4TB results, which support further evaluation of a regimen containing the compound. This study has been made possible by an outstanding collaboration: UCL’s leadership and sponsorship, together with the clinical trial expertise of the National University of Singapore team, have been essential,” says professor Michael Hoelscher, Director of the Institute of Infectious Diseases and Tropical Medicine at LMU University Hospital Munich and UNITE4TB scientific lead.
The next stage of PARADIGM4TB will test how much the treatment duration of the best-performing regimens can be shortened while maintaining long-term efficacy and preventing relapse. These findings will then need to be confirmed in potential future Phase 3 trials before the regimens could be made available to patients with TB.
“We now have two priority combinations and a clear next question: how short can treatment be while maintaining a durable response? The Phase 2C stage will help us decide which treatment duration for each of these chosen regimens would be the best to take into larger Phase 3 trials,” says Nicholas Paton, Professor at the National University of Singapore and the London School of Hygiene & Tropical Medicine, chief investigator of PARADIGM4TB and corresponding author of the study.
The UNITE4TB team are presenting these findings at The Union World Conference on Lung Health in Rio de Janeiro, Brazil, during the Late-Breaker Oral Abstracts session on 18 November 2026. A dedicated UNITE4TB symposium (SY08) explores the trial results and methodology in detail on 19 November 2026. The publication of the trial results in the New England Journal of Medicine (NEJM) will coincide with the start of the symposium.
Hanif Esmail et al.: Assessing Multiple Treatment Regimens for Tuberculosis. The New England Journal of Medicine 2026